Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient

Annals of Pharmacotherapy

Volumn 44, Issue 5, 2010, Pages 939-940

  Ibrahim, Rami B ^a,c   Abidi, Muneer H ^a,b   Al Kadhimi, Zaid ^a,b   Uberti, Joseph P ^a,b   Edwards, David J ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; TACROLIMUS;

ADULT; ASCITES FLUID; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MALE; PARACENTESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL LEUKEMIA; TREATMENT FAILURE;

ASCITIC FLUID; ERYTHROCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; MALE; MIDDLE AGED; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 77951547405     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M708     Document Type: Letter

References (5)

1. Chung M, Kozuch P. Treatment of malignant ascites. Curr Treat Options Oncol 2008;9:215-233
2. Brodoefel H, Bethge W, Vogel M, et al. Early and late-onset acute GvHD following hematopoietic cell transplantation: CT features of gastro-intestinal involvement with clinical and pathological correlation. Eur J Radiol 2010;73:594-600. DOI 10.1016/j.ejrad.2009.01.011
3. Delauter BJ, Ramanathan RK, Egorin MJ, et al. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy 2000;20:1204-1207
4. Itagaki F, Hori T, Tomita T, et al. Effect of ascites on tacrolimus disposition in a liver transplant recipient. Ther Drug Monit 2001;23:644-646 (Pubitemid 33086492)
5. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36(2 suppl):25S-32S.